SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Indirect effects of 13-valent pneumococcal conjugate vaccine on pneumococcal carriage in children hospitalised with acute respiratory infection despite heterogeneous vaccine coverage: an observational study in Lao People's Democratic Republic.

Chan, J; Lai, JYR; Nguyen, CD; Vilivong, K; Dunne, EM; Dubot-Pérès, A; Fox, K; Hinds, J; Moore, KA; Nation, ML; et al. Chan, J; Lai, JYR; Nguyen, CD; Vilivong, K; Dunne, EM; Dubot-Pérès, A; Fox, K; Hinds, J; Moore, KA; Nation, ML; Pell, CL; Xeuatvongsa, A; Vongsouvath, M; Newton, PN; Mulholland, K; Satzke, C; Dance, DAB; Russell, FM; PneuCAPTIVE Lao PDR Research Group (2021) Indirect effects of 13-valent pneumococcal conjugate vaccine on pneumococcal carriage in children hospitalised with acute respiratory infection despite heterogeneous vaccine coverage: an observational study in Lao People's Democratic Republic. BMJ Glob Health, 6 (6). e005187. ISSN 2059-7908 https://doi.org/10.1136/bmjgh-2021-005187
SGUL Authors: Hinds, Jason

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (6MB) | Preview

Abstract

INTRODUCTION: Empiric data on indirect (herd) effects of pneumococcal conjugate vaccines (PCVs) in settings with low or heterogeneous PCV coverage are limited. The indirect effects of PCV, which benefits both vaccinated and non-vaccinated individuals, are mediated by reductions in vaccine-type (VT) carriage (a prerequisite for disease). The aim of this study among hospitalised children in Lao People's Democratic Republic (Lao PDR) is to determine the effectiveness of a 13-valent PCV (PCV13) against VT pneumococcal nasopharyngeal carriage (direct effects) and the association between village-level PCV13 coverage and VT carriage (indirect effects). METHODS: Pneumococcal nasopharyngeal carriage surveillance commenced in December 2013, shortly after PCV13 introduction (October 2013). We recruited and swabbed children aged 2-59 months admitted to hospital with acute respiratory infection. Pneumococci were detected using lytA quantitative real-time PCR and serotyped using microarray. PCV13 status and village-level PCV13 coverage were determined using written immunisation records. Associations between both PCV13 status and village-level PCV13 coverage and VT carriage were calculated using generalised estimating equations, controlling for potential confounders. RESULTS: We enrolled 1423 participants and determined PCV13 coverage for 368 villages (269 863 children aged under 5 years). By 2017, median village-level vaccine coverage reached 37.5%, however, the IQR indicated wide variation among villages (24.1-56.4). Both receipt of PCV13 and the level of PCV13 coverage were independently associated with a reduced odds of VT carriage: adjusted PCV13 effectiveness was 38.1% (95% CI 4.1% to 60.0%; p=0.032); and for each per cent increase in PCV13 coverage, the estimated odds of VT carriage decreased by 1.1% (95% CI 0.0% to 2.2%; p=0.056). After adjustment, VT carriage decreased from 20.0% to 12.8% as PCV13 coverage increased from zero to 60% among under 5. CONCLUSIONS: Despite marked heterogeneity in PCV13 coverage, we found evidence of indirect effects in Lao PDR. Individual vaccination with PCV13 was effective against VT carriage.

Item Type: Article
Additional Information: Copyright information: © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Keywords: epidemiology, vaccines, Child, Humans, Laos, Pneumococcal Infections, Pneumococcal Vaccines, Serotyping, Streptococcus pneumoniae, Vaccines, Conjugate, PneuCAPTIVE Lao PDR Research Group, Humans, Streptococcus pneumoniae, Pneumococcal Infections, Pneumococcal Vaccines, Vaccines, Conjugate, Serotyping, Child, Laos
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: BMJ Glob Health
ISSN: 2059-7908
Language: eng
Dates:
DateEvent
9 June 2021Published
21 May 2021Accepted
Publisher License: Creative Commons: Attribution-Noncommercial 4.0
Projects:
Project IDFunderFunder ID
UNSPECIFIEDWellcome TrustUNSPECIFIED
001World Health OrganizationUNSPECIFIED
106698/Z/14/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
OPP1115490Bill and Melinda Gates Foundationhttp://dx.doi.org/10.13039/100000865
PubMed ID: 34108146
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/113730
Publisher's version: https://doi.org/10.1136/bmjgh-2021-005187

Actions (login required)

Edit Item Edit Item